Drug intelligence / Profile preview

terpene-enriched THC:CBD (1:1) oil

Development stage: Unknown
Lead developer: Bazelet-Tech
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral, Sublingual

Overview

Terpene-enriched THC:CBD (1:1) oil is a botanical formulation developed by Bazelet-Tech for the treatment of acute radicular pain. The drug consists of a balanced 1:1 ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), further enhanced with a specific terpene profile designed to optimize therapeutic effects through the entourage effect. It acts primarily as an agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2), modulating pain signaling and inflammatory responses. In a clinical trial (NCT04816994), the formulation demonstrated efficacy in reducing opioid consumption among patients with acute radicular pain, suggesting its potential as an opioid-sparing therapeutic option.

Other names: 1:1 THC:CBD oilterpene-enriched cannabinoid oil

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPA1 (Transient receptor potential cation channel subfamily A member 1)CNR2 (Cannabinoid receptor type 2)

Beyond the preview

Go deeper on terpene-enriched THC:CBD (1:1) oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on terpene-enriched THC:CBD (1:1) oil.

Explore the full profile